Literature DB >> 8693645

Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo.

K J Pienta1, H Naik, J E Lehr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8693645     DOI： 10.1016/s0090-4295(96)00109-4

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  10 in total

1.  Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme.

Authors:  M A Rosenthal; M L Gruber; J Glass; A Nirenberg; J Finlay; H Hochster; F M Muggia
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014.

Authors:  Howard M Sandler; Kenneth J Pienta
Journal:  Rev Urol       Date:  2003

3.  Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014.

Authors:  Howard M Sandler; Kenneth J Pienta
Journal:  Rev Urol       Date:  2003

4.  Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.

Authors:  Thomas K Hamilton; Nianping Hu; Klodiana Kolomitro; Erin N Bell; Donald H Maurice; Charles H Graham; D Robert Siemens
Journal:  World J Urol       Date:  2012-03-02       Impact factor: 4.226

5.  Evaluation of novel 111In-labeled gonadotropin-releasing hormone peptides for human prostate cancer imaging.

Authors:  Jingli Xu; Changjian Feng; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2017-09-07       Impact factor: 2.823

6.  A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging.

Authors:  Haixun Guo; Fabio Gallazzi; Larry A Sklar; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2011-07-23       Impact factor: 2.823

Review 7.  Oral chemotherapy in the treatment of hormone-refractory prostate cancer.

Authors:  K J Pienta; J M Kamradt; D C Smith
Journal:  Drugs       Date:  1999       Impact factor: 9.546

8.  Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.

Authors:  Ercument Cengiz; Burcak Karaca; Yuksel Kucukzeybek; Gurbuz Gorumlu; Mustafa K Gul; Cigdem Erten; Harika Atmaca; Selim Uzunoglu; Bulent Karabulut; Ulus A Sanli; Ruchan Uslu
Journal:  Mol Biol Rep       Date:  2009-03-14       Impact factor: 2.316

9.  Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.

Authors:  Jonathan Ma; Sadhika Malladi; Andrew H Beck
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

Review 10.  Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.

Authors:  Tomasz M Beer; Joseph S Bubalo
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.